Induced Myeloid Leukemia Cell Differentiation Protein Mcl-1 (Bcl-2-Like Protein 3 or Bcl-2-Related Protein EAT/Mcl1) - Pipeline Review, H1 2016 - Global Markets Direct - Market Research

Induced Myeloid Leukemia Cell Differentiation Protein Mcl-1 (Bcl-2-Like Protein 3 or Bcl-2-Related Protein EAT/Mcl1) - Pipeline Review, H1 2016

Induced Myeloid Leukemia Cell Differentiation Protein Mcl-1 (Bcl-2-Like Protein 3 or Bcl-2-Related Protein EAT/Mcl1) - Pipeline Review, H1 2016 - Global Markets Direct - Market Research
Induced Myeloid Leukemia Cell Differentiation Protein Mcl-1 (Bcl-2-Like Protein 3 or Bcl-2-Related Protein EAT/Mcl1) - Pipeline Review, H1 2016
Published Jun 28, 2016
60 pages — Published Jun 28, 2016
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Induced Myeloid Leukemia Cell Differentiation Protein Mcl-1 (Bcl-2-Like Protein 3 or Bcl-2-Related Protein EAT/Mcl1) - Pipeline Review, H1 2016, provides in depth analysis on Induced Myeloid Leukemia Cell Differentiation Protein Mcl-1 (Bcl-2-Like Protein 3 or Bcl-2-Related Protein EAT/Mcl1) targeted pipeline therapeutics.

The report provides comprehensive information on the Induced Myeloid Leukemia Cell Differentiation Protein Mcl-1 (Bcl-2-Like Protein 3 or Bcl-2-Related Protein EAT/Mcl1), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Induced Myeloid Leukemia Cell Differentiation Protein Mcl-1 (Bcl-2-Like Protein 3 or Bcl-2-Related Protein EAT/Mcl1) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Induced Myeloid Leukemia Cell Differentiation Protein Mcl-1 (Bcl-2-Like Protein 3 or Bcl-2-Related Protein EAT/Mcl1)
- The report reviews Induced Myeloid Leukemia Cell Differentiation Protein Mcl-1 (Bcl-2-Like Protein 3 or Bcl-2-Related Protein EAT/Mcl1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Induced Myeloid Leukemia Cell Differentiation Protein Mcl-1 (Bcl-2-Like Protein 3 or Bcl-2-Related Protein EAT/Mcl1) targeted therapeutics and enlists all their major and minor projects
- The report assesses Induced Myeloid Leukemia Cell Differentiation Protein Mcl-1 (Bcl-2-Like Protein 3 or Bcl-2-Related Protein EAT/Mcl1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Induced Myeloid Leukemia Cell Differentiation Protein Mcl-1 (Bcl-2-Like Protein 3 or Bcl-2-Related Pro

  
Source:
Document ID
GMDHC0142TDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents24
  List of Tables51
  List of Figures51
Introduction61
  Global Markets Direct Report Coverage61
Induced Myeloid Leukemia Cell Differentiation Protein Mcl-1 (Bcl-2-Like Protein 3 or Bcl-2-Related Protein EAT/Mcl1) Overview71
Therapeutics Development83
  Induced Myeloid Leukemia Cell Differentiation Protein Mcl-1 (Bcl-2-Like Protein 3 or Bcl-2-Related Protein EAT/Mcl1) Products under Development by Stage of Development81
  Induced Myeloid Leukemia Cell Differentiation Protein Mcl-1 (Bcl-2-Like Protein 3 or Bcl-2-Related Protein EAT/Mcl1) Products under Development by Therapy Area91
  Induced Myeloid Leukemia Cell Differentiation Protein Mcl-1 (Bcl-2-Like Protein 3 or Bcl-2-Related Protein EAT/Mcl1) Products under Development by Indication101
Induced Myeloid Leukemia Cell Differentiation Protein Mcl-1 (Bcl-2-Like Protein 3 or Bcl-2-Related Protein EAT/Mcl1) Pipeline Products Glance112
  Late Stage Products111
  Early Stage Products121
Induced Myeloid Leukemia Cell Differentiation Protein Mcl-1 (Bcl-2-Like Protein 3 or Bcl-2-Related Protein EAT/Mcl1) Products under Development by Companies132
Induced Myeloid Leukemia Cell Differentiation Protein Mcl-1 (Bcl-2-Like Protein 3 or Bcl-2-Related Protein EAT/Mcl1) Products under Development by Universities/Institutes152
Induced Myeloid Leukemia Cell Differentiation Protein Mcl-1 (Bcl-2-Like Protein 3 or Bcl-2-Related Protein EAT/Mcl1) Therapeutics Assessment175
  Assessment by Monotherapy/Combination Products171
  Assessment by Mechanism of Action181
  Assessment by Route of Administration191
  Assessment by Molecule Type202
Induced Myeloid Leukemia Cell Differentiation Protein Mcl-1 (Bcl-2-Like Protein 3 or Bcl-2-Related Protein EAT/Mcl1) Companies Involved in Therapeutics Development225
  AbbVie Inc.221
  Complix NV231
  Les Laboratoires Servier SAS241
  Princeton University251
  Takeda Pharmaceutical Company Limited261
Induced Myeloid Leukemia Cell Differentiation Protein Mcl-1 (Bcl-2-Like Protein 3 or Bcl-2-Related Protein EAT/Mcl1) Drug Profiles2716
  AT-101 Drug Profile274
  FL-118 Drug Profile312
  Proteins to Inhibit MCL-1 for Oncology Drug Profile331
  Small molecule to Inhibit Bcl-x Protein and MCL-1 for Oncology Drug Profile341
  Small Molecule to Inhibit Mcl-1 for Cancer Drug Profile351
  Small Molecules to Inhibit Mcl-1 and Bcl-xL for Oncology Drug Profile361
  Small Molecules to Inhibit Mcl-1 and Bcl-xL for Oncology Drug Profile371
  Small Molecules to Inhibit MCL-1 for Breast Cancer Drug Profile381
  Small Molecules to Inhibit MCL-1 for Cancer Drug Profile391
  Small Molecules to Inhibit MCL-1 for Oncology Drug Profile401
  Synthetic Peptides to Inhibit Bcl-x and MCL-1 for Oncology Drug Profile411
  UMI-77 Drug Profile421
Induced Myeloid Leukemia Cell Differentiation Protein Mcl-1 (Bcl-2-Like Protein 3 or Bcl-2-Related Protein EAT/Mcl1) Dormant Projects433
Induced Myeloid Leukemia Cell Differentiation Protein Mcl-1 (Bcl-2-Like Protein 3 or Bcl-2-Related Protein EAT/Mcl1) Featured News &Press Releases4613
  Apr 28, 2015: Camptothecin Analog FL118 Can Overcome Treatment Resistance, Outperform Approved Therapies461
  Dec 15, 2014: Roswell Park Study Suggests Additional Applications for FL118 as Personalized Therapy for Cancer462
  Dec 31, 2013: Scientists Identify Key Structural Qualities that Distinguish Novel Anticancer Agent481
  Dec 31, 2013: Scientists Identify Key Structural Qualities that Distinguish Novel Anticancer Agent491
  Apr 02, 2013: Roswell Park Scientists Advance Findings about Novel, Low-Toxicity Anticancer Agent491
  Sep 20, 2012: RPCI Scientists Publish Findings About Novel Anticancer Agent501
  Jun 01, 2009: Ascenta Therapeutics Announces Multiple Presentations On AT-101 At 2009 ASCO Annual Meeting511
  Jun 01, 2009: Ascenta Therapeutics Announces Presentation Of Promising Results From Clinical Trials Of AT-101 In Prostate, Brain, And Lung Cancers At 2009 Asco Annual Meeting512
  Jun 01, 2009: Ascenta Therapeutics Announces Presentation Of Promising Results From Clinical Trials Of AT-101 In Prostate, Brain, And Lung cancers At 2009 Asco Annual Meeting531
  May 26, 2009: Ascenta Therapeutics Announces Multiple Presentations On AT-101 At 2009 Asco Annual Meeting541
  May 26, 2009: Ascenta Therapeutics Announces Multiple Presentations On AT-101 At 2009 ASCO Annual Meeting541
  Feb 27, 2009: Ascenta Therapeutics Announces Positive Preliminary Results With AT-101 In Docetaxel Refactory Prostate Cancer542
  Feb 23, 2007: Ascenta Therapeutics Presents New Clinical Data On AT-101 Monotherapy for the Treatment of Hormone-Refractory Prostate Cancer561
  Dec 10, 2006: Ascenta Therapeutics Presents New Clinical and Biological Data on AT-101 for the Treatment of Chronic Lymphocytic Leukemia561
  Jun 05, 2006: Clinical Data On Ascenta Therapeutics Lead Product AT-101 Presented At The 2006 American Society For Clinical Oncology Annual Meeting572
Appendix592
  Methodology591
  Coverage591
  Secondary Research591
  Primary Research591
  Expert Panel Validation591
  Contact Us591
  Disclaimer601

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Induced Myeloid Leukemia Cell Differentiation Protein Mcl-1 (Bcl-2-Like Protein 3 or Bcl-2-Related Protein EAT/Mcl1) - Pipeline Review, H1 2016" Jun 28, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Induced-Myeloid-Leukemia-Cell-Differentiation-Protein-Mcl-1-Bcl-2-Like-Protein-3-or-Bcl-2-Related-Protein-EAT-Mcl1-Pipeline-Review-H1-2016-2088-16044>
  
APA:
Global Markets Direct - Market Research. (2016). Induced Myeloid Leukemia Cell Differentiation Protein Mcl-1 (Bcl-2-Like Protein 3 or Bcl-2-Related Protein EAT/Mcl1) - Pipeline Review, H1 2016 Jun 28, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Induced-Myeloid-Leukemia-Cell-Differentiation-Protein-Mcl-1-Bcl-2-Like-Protein-3-or-Bcl-2-Related-Protein-EAT-Mcl1-Pipeline-Review-H1-2016-2088-16044>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.